T1	PROC 46 62	Estudio fase III
T2	PROC 372 380	tratados
#1	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	DISO 104 123	hipercolesterolemia
#2	AnnotatorNotes T3	C0020443; Hypercholesterolemia; Disease or Syndrome
T4	CHEM 144 152	estatina
#3	AnnotatorNotes T4	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T5	PROC 195 273	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos
T6	DISO 575 579	heFH
#4	AnnotatorNotes T6	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T7	PROC 278 308	evalúa la eficacia y seguridad
T8	DISO 340 368	hipercolesterolemia primaria
#5	AnnotatorNotes T8	C0342879; Primary hypercholesterolemia; Disease or Syndrome
T9	CHEM 389 397	estatina
#6	AnnotatorNotes T9	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T10	CHEM 438 448	colesterol
#7	AnnotatorNotes T10	C0008377; cholesterol; Biologically Active Substance · Organic Chemical
T11	ANAT 452 458	sangre
#8	AnnotatorNotes T11	C0005767; Blood; Body Substance
T12	DISO 485 504	Hipercolesterolemia
#9	AnnotatorNotes T12	C0020443; Hypercholesterolemia; Disease or Syndrome
T13	DISO 545 573	hipercolesterolemia primaria
#10	AnnotatorNotes T13	C0342879; Primary hypercholesterolemia; Disease or Syndrome
T14	DISO 585 587	FH
#11	AnnotatorNotes T14	C0020445; Hypercholesterolemia, Familial; Disease or Syndrome
T15	CHEM 613 624	fenofibrato
#12	AnnotatorNotes T15	C0033228; fenofibrate; Organic Chemical · Pharmacologic Substance
T16	ANAT 679 681	CV
#13	AnnotatorNotes T16	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T17	CHEM 601 610	ezetimiba
#14	AnnotatorNotes T17	C1142985; ezetimibe; Organic Chemical · Pharmacologic Substance
T18	ANAT 782 784	CV
#15	AnnotatorNotes T18	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T19	PROC 1007 1010	TML
#16	AnnotatorNotes T19	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T20	DISO 1062 1073	intolerante
T21	CHEM 1015 1024	estatinas
#17	AnnotatorNotes T21	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T22	CHEM 1076 1085	estatinas
#18	AnnotatorNotes T22	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T23	CHEM 312 322	Alirocumab
#19	AnnotatorNotes T23	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	DISO 672 681	riesgo CV
#20	AnnotatorNotes T24	C4324389; Cardiovascular Risk; Finding
T25	DISO 421 458	Niveles altos de colesterol en sangre
T26	PROC 633 638	dieta
#21	AnnotatorNotes T26	C0012159; Diet therapy; Health Care Activity | C0600072; Feeding and dietary regimes; Therapeutic or Preventive Procedure
T27	PROC 693 698	LDL-C
T28	PROC 803 808	LDL-C
T29	PROC 885 890	LDL-C
T30	PROC 974 979	dieta
#22	AnnotatorNotes T30	C0012159; Diet therapy; Health Care Activity | C0600072; Feeding and dietary regimes; Therapeutic or Preventive Procedure
T31	CHEM 76 86	Alirocumab
#23	AnnotatorNotes T31	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	DISO 775 784	riesgo CV
#24	AnnotatorNotes T32	C4324389; Cardiovascular Risk; Finding
T33	PROC 127 135	tratados
#25	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	Date 13 17	2013
T35	LIVB 90 99	pacientes
#26	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Neg_cue 124 126	no
T37	LIVB 326 335	pacientes
#27	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Neg_cue 369 371	no
T39	LIVB 531 540	Pacientes
#28	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T47	LIVB 982 991	pacientes
#29	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	Neg_cue 1011 1014	sin
T49	Neg_cue 1034 1036	no
T40	Date 751 759	semana-3
T41	Date 864 872	semana-3
T42	Date 945 953	semana-3
T43	PROC 730 749	visita de selección
#30	AnnotatorNotes T43	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T44	PROC 843 862	visita de selección
#31	AnnotatorNotes T44	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T45	PROC 924 943	visita de selección
#32	AnnotatorNotes T45	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A2	Assertion T21 Negated
A3	Assertion T20 Negated
A4	Assertion T22 Negated
A5	Assertion T33 Negated
A6	Assertion T4 Negated
A7	Assertion T2 Negated
A8	Assertion T9 Negated
#33	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity
#34	AnnotatorNotes T5	C0013072; Double-Blind Method; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product  + C2826345; Parallel Study; Research Activity 
#35	AnnotatorNotes T7	C0511730; Identify product efficacy and safety issues; Health Care Activity
#36	AnnotatorNotes T25	C0020443; Hypercholesterolemia; Disease or Syndrome | C3842522; High blood cholesterol; Finding
#37	AnnotatorNotes T27	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
#38	AnnotatorNotes T28	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
#39	AnnotatorNotes T29	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
#40	AnnotatorNotes T20	C0277585; Intolerance to drug; Pathologic Function
T46	Neg_cue 582 584	no
A1	Assertion T14 Negated
R1	Negation Arg1:T46 Arg2:T14	
R2	Experiences Arg1:T39 Arg2:T13	
R3	Experiences Arg1:T39 Arg2:T6	
R4	Experiences Arg1:T39 Arg2:T14	
R5	Experiences Arg1:T39 Arg2:T17	
R6	Experiences Arg1:T39 Arg2:T15	
R7	Experiences Arg1:T39 Arg2:T26	
T50	Quantifier_or_Qualifier 628 632	solo
R8	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T50	
R9	Experiences Arg1:T35 Arg2:T31	
R10	Experiences Arg1:T35 Arg2:T3	
R11	Negation Arg1:T36 Arg2:T33	
R12	Experiences Arg1:T35 Arg2:T33	
R13	Used_for Arg1:T4 Arg2:T33	
R14	Experiences Arg1:T35 Arg2:T4	
R15	Experiences Arg1:T37 Arg2:T23	
R16	Experiences Arg1:T37 Arg2:T8	
R17	Experiences Arg1:T37 Arg2:T2	
R18	Negation Arg1:T38 Arg2:T2	
R19	Used_for Arg1:T9 Arg2:T2	
R20	Negation Arg1:T38 Arg2:T9	
R21	Location_of Arg1:T11 Arg2:T25	
R22	Location_of Arg1:T16 Arg2:T24	
T51	Quantifier_or_Qualifier 682 690	muy alto
R23	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T51	
T52	Result_or_Value 699 723	< 70 mg/dl (1,81 mmol/l)
R24	Has_Result_or_Value Arg1:T27 Arg2:T52	
R25	Overlap Arg1:T27 Arg2:T43	
R26	Overlap Arg1:T27 Arg2:T40	
R27	Overlap Arg1:T43 Arg2:T40	
T53	Quantifier_or_Qualifier 785 789	alto
#41	AnnotatorNotes T53	C0205250; High; Qualitative Concept
R28	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T53	
R29	Location_of Arg1:T18 Arg2:T32	
T54	Quantifier_or_Qualifier 792 800	moderado
#42	AnnotatorNotes T54	C0205081; Moderate (severity modifier); Qualitative Concept
R30	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T54	
T55	Result_or_Value 809 836	< 100 mg/dl (< 2,59 mmol/l)
R31	Has_Result_or_Value Arg1:T28 Arg2:T55	
R32	Overlap Arg1:T28 Arg2:T41	
R33	Overlap Arg1:T28 Arg2:T44	
T56	Result_or_Value 891 917	> 160 mg/dl (> 4,1 mmol/l)
R34	Has_Result_or_Value Arg1:T29 Arg2:T56	
R35	Overlap Arg1:T29 Arg2:T45	
R36	Overlap Arg1:T45 Arg2:T42	
R37	Overlap Arg1:T29 Arg2:T42	
T57	Quantifier_or_Qualifier 969 973	solo
R38	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T57	
R39	Overlap Arg1:T29 Arg2:T30	
R40	Experiences Arg1:T47 Arg2:T30	
R41	Experiences Arg1:T47 Arg2:T29	
R42	Experiences Arg1:T47 Arg2:T19	
R43	Used_for Arg1:T21 Arg2:T19	
R44	Negation Arg1:T48 Arg2:T21	
R45	Overlap Arg1:T29 Arg2:T19	
R46	Negation Arg1:T49 Arg2:T20	
R47	Causes Arg1:T22 Arg2:T20	
R48	Experiences Arg1:T47 Arg2:T20	
#43	AnnotatorNotes T50	C0205171; Singular; Quantitative Concept
#44	AnnotatorNotes T57	C0205171; Singular; Quantitative Concept
A9	Experiencer T35 Patient
A10	Experiencer T37 Patient
A11	Experiencer T39 Patient
A12	Assertion T57 Hypothetical
A13	Assertion T30 Hypothetical
A14	Experiencer T47 Patient
